Danielle de Jong
Overview
Explore the profile of Danielle de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1404
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pierneef L, van Hooij A, de Jong D, Wassenaar G, Verhard E, Tjon Kon Fat E, et al.
Infect Dis Poverty
. 2024 Dec;
13(1):88.
PMID: 39617937
Background: Detection of infection with Mycobacterium leprae allows timely prophylactic treatment, thereby reducing transmission as well as the risk of permanent, leprosy-associated nerve damage. However, since there is no worldwide-implemented...
2.
de Jong D, Carrell C, Maganga J, Mhango L, Shigella P, Gill M, et al.
Diagnostics (Basel)
. 2024 Apr;
14(8).
PMID: 38667466
A laboratory-based lateral flow (LF) test that utilizes up-converting reporter particles (UCP) for ultrasensitive quantification of circulating anodic antigen (CAA) in urine is a well-accepted test to identify active infection....
3.
Schnitzler C, Chang E, Waletich J, Quiroga-Artigas G, Wong W, Nguyen A, et al.
Genome Res
. 2024 Mar;
34(3):498-513.
PMID: 38508693
is a colonial marine hydroid that shows remarkable biological properties, including the capacity to regenerate its entire body throughout its lifetime, a process made possible by its adult migratory stem...
4.
Loos N, Ferreira Martins M, Rijmers J, de Jong D, Lebre M, Tibben M, et al.
Mol Pharm
. 2024 Feb;
21(4):1952-1964.
PMID: 38423793
Intravenously administered chemotherapeutic cabazitaxel is used for palliative treatment of prostate cancer. An oral formulation would be more patient-friendly and reduce the need for hospitalization. We therefore study determinants of...
5.
Loos N, F Martins M, de Jong D, Lebre M, Tibben M, Beijnen J, et al.
Int J Pharm
. 2023 Dec;
650:123708.
PMID: 38135258
Developing an oral formulation for the chemotherapeutic cabazitaxel might improve its patient-friendliness, costs, and potentially exposure profile. Cabazitaxel oral availability is restricted by CYP3A-mediated first-pass metabolism, but can be substantially...
6.
Pierneef L, Malaviya P, van Hooij A, Sundar S, Singh A, Kumar R, et al.
Front Med (Lausanne)
. 2023 Oct;
10:1260375.
PMID: 37828950
Background: It has been amply described that levels of IgM antibodies against () phenolic glycolipid I (PGL-I) correlate strongly with the bacterial load in an infected individual. These findings have...
7.
Schnitzler C, Chang E, Waletich J, Quiroga-Artigas G, Wong W, Nguyen A, et al.
bioRxiv
. 2023 Oct;
PMID: 37786714
is a colonial marine hydroid that exhibits remarkable biological properties, including the capacity to regenerate its entire body throughout its lifetime, a process made possible by its adult migratory stem...
8.
Khalid H, Pierneef L, van Hooij A, Zhou Z, de Jong D, Tjon Kon Fat E, et al.
Front Vet Sci
. 2023 Sep;
10:1193332.
PMID: 37655261
Bovine tuberculosis (bTB), caused by () infection in cattle, is an economically devastating chronic disease for livestock worldwide. Efficient disease control measures rely on early and accurate diagnosis using the...
9.
Buijsse N, Jansen F, Ockeloen C, van Kempen M, Zeidler S, Willemsen M, et al.
Epilepsia Open
. 2023 Jul;
8(4):1300-1313.
PMID: 37501353
Objective: The aim of this study was to describe the epilepsy phenotype in a large international cohort of patients with KBG syndrome and to study a possible genotype-phenotype correlation. Methods:...
10.
Loos N, F Martins M, de Jong D, Lebre M, Tibben M, Beijnen J, et al.
Mol Pharm
. 2023 Mar;
20(5):2477-2489.
PMID: 36976574
There is currently great interest in developing oral taxanes due to their lower costs and greater patient friendliness. We here wanted to test whether oral ritonavir, a cytochrome P450 3A...